S
Sound Pharmaceuticals
Development of prescription drugs for the prevention and treatment of hearing loss and vertigo
About Sound Pharmaceuticals
Sound Pharmaceuticals is a biopharmaceutical company founded in 2002 by Jonathan Kil, MD, who currently serves as CEO and CMO. With a background in auditory neuroscience and otolaryngology, Dr. Kil previously co-founded Otogene in 1998, the first inner ear biopharmaceutical company.
Sound Pharmaceuticals focuses on the development of prescription drugs for the prevention and treatment of hearing loss. The company operates in the specialty biopharmaceutical market, developing novel treatments for various forms of hearing loss. Its business model revolves around the research and development of these therapeutics, with the aim of bringing them to market. The company is also involved in the vertigo drugs market.
Source: Dealroom company dataAt a glance
- Founded
- 2001
- Headquarters
- Seattle, United States
- Sector
- Biotech & Life Sciences
News
Open roles
Sound Pharmaceuticals in the Seattle ecosystem
The Sound Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Cystic Fibrosis Foundation
National Center For Advancing Translational Sciences
Series B and later1 investor entered at this stage
KEC Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sound Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sound Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

